Verona Pharma Plc's Customers Performance

Name: Verona Pharma Plc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

VRNA

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


VRNA's Source of Revenues		During the corresponding time, Verona Pharma Plc sequentially revenue grew by 35.25 %. While revenue at the Verona Pharma Plc's corporate clients • List of VRNA Customers

for the same period Verona Pharma Plc sequentially revenue grew by 35.25 %.

• List of VRNA Customers

Verona Pharma Plc's Business Units


Special Pharmacy 1	0 %	of total Revenue
Special Pharmacy 2	0 %	of total Revenue
Special Pharmacy 3	0 %	of total Revenue
Special Pharmacy 4	0 %	of total Revenue
Special Pharmacy 5	0 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Verona Pharma Plc's Comment on Sales, Marketing and Customers

News about Verona Pharma Plc Contracts

Verona Pharma to Unveil Pioneering COPD Research Insights at ERS 2024 Congress,

Verona Pharma Plc, a rising star in respiratory therapeutics, is set to present a comprehensive suite of findings from its successful Phase 3 ENHANCE studies involving Ohtuvayre, a novel treatment for Chronic Obstructive Pulmonary Disease (COPD). The company s impactful research will be highlighted through one oral presentation and three posters at the prestigious European Respiratory Society (ERS) International Congress 2024. This event marks a significant opportunity for Verona Pharma to share pivotal data with the global respiratory community.The ENHANCE studies, designed to scrutinize the efficacy and safety profile of Ohtuvayre, have previously demonstrated promising outcomes. These findings have the po...

Verona Pharma Plc, a renowned biopharmaceutical company, has recently achieved a significant milestone with...

Verona Pharma s Ohtuvayre (ensifentrine) Receives FDA Approval for COPD Maintenance Treatment, Boosting Revenue ProspectsVerona Pharma Plc, a renowned biopharmaceutical company, has recently achieved a significant milestone with the US Food and Drug Administration (FDA) granting approval for its novel medication, Ohtuvayre (ensifentrine). This groundbreaking drug is now cleared for use in the maintenance treatment of chronic obstructive pulmonary disease (COPD) among adult patients. Verona Pharma s acquisition of this approval represents a major triumph for the company and offers a new ray of hope for individuals suffering from this debilitating condition.COPD is a progressive lung disease characterized by r...

VRNA's Stock Performance relative to it's Customers

VRNA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Verona Pharma Plc	9,718.43	221.67	-81.19	79
SUBTOTAL	0.00	0.00	0.00	-

Sources: Verona Pharma Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Verona Pharma Plc’s corporate clients.
For your research, we’ve provided 9 tables on Verona Pharma Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.